ClinicalTrials.gg
CompletedNCT02690207Updated Mar 4, 2021Results posted

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

A Phase 3 interventional study of Herpes Zoster Vaccine GSK1437173A in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 195 sites in 18 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-04.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8,687
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
5th of 46
8,687 · median 239
Started
2016
with 2 others
Phase 3
22 of 46
2 open now
Registered
17th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 5th largest by enrollment, is one of 3 that started in 2016, is one of 22 in phase 3, and was the 17th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects >= 50 Years of age (YOA) who previously received placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229).

Read the detailed description

Since the HZ/su vaccine has not yet been licensed and marketed, this study is being conducted to enable potentially eligible subjects who previously received placebo in ZOSTER-006 (NCT01165177) or ZOSTER-022 (NCT01165229) to receive the HZ/su vaccine.

Study ZOSTER-056 is an open-label, multi-centric and single arm study to cross-vaccinate and collect safety data in terms of of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and pIMD from subjects >= 50 YOA who previously received placebo.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Herpes Zoster
  • Safety
  • Adults
  • Cross-vaccination
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, vaccination visits, follow-up contacts). Or subjects' Legally Acceptable Representative(s) [LAR(s)]/caregiver who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, vaccination visits, availability for follow-up contacts).
  • Written obtained from the subject/Legally Acceptable representative(s) [LAR(s)] of the subject prior to performing any study specific procedure. If the subjects is not capable of giving consent, his/her assent to participate should be obtained to the extent possible.
  • Subject who previously participated in ZOSTER-006 or ZOSTER-022 studies and received at least one dose of placebo.
  • Female subjects of non- may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or .
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination and
    • has agreed to continue adequate contraception during the entire treatment period* and for 2 months after completion of the vaccination series.

      • treatment period refers to vaccination days and the interval between them.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine during the period starting 30 days before the first dose of study vaccine (Day -29 to Day 0), or planned use up to 30 days post Dose 2.
  • Previous vaccination against Varicella Zoster virus (VZV) or HZ.
  • Planned administration of VZV or HZ vaccination during the study (including an investigational or non-registered vaccine), with the exception of the study vaccine.
  • Planned administration/administration of a vaccine/product not foreseen by the study protocol in the period starting 30 days before the first dose and ending 30 days after the last dose of vaccine administration, with the exception of licensed non-replicating vaccines (i.e. inactivated and subunit vaccines, including inactivated and subunit influenza vaccines, with or without adjuvant for seasonal or pandemic flus). These may be administered up to 8 days prior to dose 1 and/or dose 2 and/or at least 14 days after any dose of study vaccine
  • Chronic administration (defined as more than 14 days in total) of or other immune-modifying drugs during the period starting six months prior to the first vaccine dose and up to 30 days post Dose 2. For , this will mean prednisone ≥ 20 mg/day or equivalent. Inhaled, topical and intra-articular corticosteroids are allowed.
  • Administration of long-acting immune-modifying drugs (e.g. infliximab, rituximab) within six months prior to the first vaccine dose up to 30 days post Dose 2.
  • Concurrently participating in another clinical study, at the time of enrolment or planned participation up to the 30 days post second dose, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., , [HIV] infection) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat disorders).
  • History of any reaction or likely to be exacerbated by any component of the vaccine.
  • Active HZ infection at the time of enrolment (i.e. HZ lesions not completely crusted over).
  • Pregnant or lactating female.
  • Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.
  • Any condition which in the judgment of the investigator would make intramuscular injection unsafe.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8,687 participants (actual)

Study arms

  • Experimental
    HZ/su Group

    Subjects received Herpes Zoster subunit vaccine, administered intramuscularly (IM) in the deltoid of the non-dominant arm

    Biological: Herpes Zoster Vaccine GSK1437173A

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related=AE assessed by the investigator as related to the vaccination.

    Time frame: During 30 days (Days 0-29) after any vaccination (across doses)

  2. Number of Subjects With Any and Related Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity. Related=SAE assessed by the investigator as related to the vaccination.

    Time frame: From Month 0 until study end (Month 14, i.e. 12 months post dose 2)

  3. Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related pIMDs=pIMDs assessed by the investigator as related to the vaccination.

    Time frame: From Month 0 until study end (Month 14, i.e. 12 months post dose 2)

Secondary outcomes

  1. Number of Subjects With at Least One Suspected Herpes Zoster (HZ) Case(s)

    A suspected case of HZ was defined as a new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations). Clinically confirmed HZ episode is suspected HZ episode confirmed by the Investigator/Delegate.

    Time frame: From Month 0 until study end (Month 14, i.e. 12 months post dose 2)

07

Results

Posted Mar 12, 2020

Participant flow

Potentially eligible subjects who received placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) studies were enrolled in this study.

Participant flow — Overall Study
MilestoneHZ/su Group
Started8687
Completed8434
Not completed253
Withdrew: Lost to follow-up48
Withdrew: Withdrawal by subject46
Withdrew: Protocol violation2
Withdrew: Serious adverse event110
Withdrew: Non-serious adverse event18
Withdrew: Migrated/moved from study area5
Withdrew: Suspected hz episode1
Withdrew: Other reasons for withdrawal23

Outcome measures

PrimaryNumber of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related=AE assessed by the investigator as related to the vaccination.

Time frame:
During 30 days (Days 0-29) after any vaccination (across doses)
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
ParticipantsHZ/su Group
Any AE(s)5175
Grade 3 AE(s)963
Related AE(s)4422
PrimaryNumber of Subjects With Any and Related Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity. Related=SAE assessed by the investigator as related to the vaccination.

Time frame:
From Month 0 until study end (Month 14, i.e. 12 months post dose 2)
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related Serious Adverse Events (SAEs)
ParticipantsHZ/su Group
Any SAE(s)734
Related SAE(s)2
PrimaryNumber of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related pIMDs=pIMDs assessed by the investigator as related to the vaccination.

Time frame:
From Month 0 until study end (Month 14, i.e. 12 months post dose 2)
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)
ParticipantsHZ/su Group
Any pIMD(s)62
Related pIMD(s)1
SecondaryNumber of Subjects With at Least One Suspected Herpes Zoster (HZ) Case(s)

A suspected case of HZ was defined as a new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations). Clinically confirmed HZ episode is suspected HZ episode confirmed by the Investigator/Delegate.

Time frame:
From Month 0 until study end (Month 14, i.e. 12 months post dose 2)
Reported as:
Count of participants · Participants
Number of Subjects With at Least One Suspected Herpes Zoster (HZ) Case(s)
ParticipantsHZ/su Group
HZ episode30
Suspected HZ episode only8
Clinically confirmed HZ episode22

Adverse events

Collected over Unsolicited AEs were collected during the 30 days (Days 0-29) follow-up period after any vaccination (across doses). SAEs were collected from Month 0 until study end (Month 14, i.e. 12 months post dose 2).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HZ/su Group107/8,687 (1.2%)734/8,687 (8.4%)5,101/8,687 (58.7%)
Most frequent serious events
Showing 10 of 448
Most frequent serious events
EventHZ/su Group
PneumoniaInfections and infestations54/8687
Cardiac failureCardiac disorders28/8687
Atrial fibrillationCardiac disorders25/8687
Acute myocardial infarctionCardiac disorders18/8687
Myocardial infarctionCardiac disorders18/8687
Urinary tract infectionInfections and infestations17/8687
OsteoarthritisMusculoskeletal and connective tissue disorders15/8687
Cardiac failure congestiveCardiac disorders14/8687
Cerebrovascular accidentNervous system disorders14/8687
Angina pectorisCardiac disorders12/8687
Most frequent other events
Showing 10 of 622
Most frequent other events
EventHZ/su Group
Injection site painGeneral disorders3173/8687
Injection site erythemaGeneral disorders1311/8687
PyrexiaGeneral disorders1038/8687
Injection site swellingGeneral disorders928/8687
HeadacheNervous system disorders678/8687
MyalgiaMusculoskeletal and connective tissue disorders386/8687
FatigueGeneral disorders384/8687
ChillsGeneral disorders319/8687
Injection site pruritusGeneral disorders248/8687
NasopharyngitisInfections and infestations228/8687

Baseline characteristics

Age, Continuous
Age, Continuous(Years)HZ/su Group
Mean72.6 ± 9.4
Age, Customized
Age, Customized(Participants)HZ/su Group
Age 18-64 years2326
Age 65-84 years5574
Age 85 years and over787
Sex/Gender, Customized
Sex/Gender, Customized(Participants)HZ/su Group
Female5254
Male3433
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)HZ/su Group
African Heritage/ African American72
American Indian or Alaskan Native7
Asian-Central/South Asian Heritage5
Asian-East Asian Heritage1202
Asian-Japanese Heritage254
Asian-South East Asian Heritage12
Native Hawaiian or Other Pacific Islander3
White-Arabic/North African Heritage47
White-Caucasian / European Heritage6361
Other724
08

Study locations

195 sites
  • GSK Investigational Site
    Mesa, Arizona 85213, United States
  • GSK Investigational Site
    Phoenix, Arizona 85018, United States
  • GSK Investigational Site
    Phoenix, Arizona 85020, United States
  • GSK Investigational Site
    Phoenix, Arizona 85050, United States
  • GSK Investigational Site
    Tucson, Arizona 85712, United States
  • GSK Investigational Site
    Spring Valley, California 91978, United States
  • GSK Investigational Site
    Clearwater, Florida 33761, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Jacksonville, Florida 32205, United States
  • GSK Investigational Site
    Jacksonville, Florida 32216, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
  • GSK Investigational Site
    Meridian, Idaho 83642, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    Columbia, Maryland 21045, United States
  • GSK Investigational Site
    Elkridge, Maryland 21075, United States
  • GSK Investigational Site
    Kansas City, Missouri 64114, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89104, United States
  • GSK Investigational Site
    Somers Point, New Jersey 08244, United States
  • GSK Investigational Site
    Cary, North Carolina 27518, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Hickory, North Carolina 28601, United States
  • GSK Investigational Site
    Salisbury, North Carolina 28144, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Cleveland, Ohio 44122, United States
  • GSK Investigational Site
    Wadsworth, Ohio 44281, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15236, United States
  • GSK Investigational Site
    Uniontown, Pennsylvania 15401, United States
  • GSK Investigational Site
    Greer, South Carolina 29651, United States
  • GSK Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    Bristol, Tennessee 37620, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Murray, Utah 84123, United States
  • GSK Investigational Site
    Newport News, Virginia 23606, United States
  • GSK Investigational Site
    Richmond, Virginia 23294, United States
  • GSK Investigational Site
    Winchester, Virginia 22601, United States
  • GSK Investigational Site
    Renton, Washington 98057, United States
  • GSK Investigational Site
    Maroubra, New South Wales 2035, Australia
  • GSK Investigational Site
    Umina, New South Wales 2257, Australia
  • GSK Investigational Site
    Westmead, New South Wales 2145, Australia
  • GSK Investigational Site
    Wollongong, New South Wales 2522, Australia
  • GSK Investigational Site
    Kippa Ring, Queensland 4021, Australia
  • GSK Investigational Site
    Geelong, Victoria 3220, Australia
  • GSK Investigational Site
    Ivanhoe, Victoria 3079, Australia
  • GSK Investigational Site
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • GSK Investigational Site
    Curitiba, Paraná 80810-050, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90035003, Brazil
  • GSK Investigational Site
    Curitiba/PR, 80240-280, Brazil
  • GSK Investigational Site
    São Paulo, 04023-900, Brazil
  • GSK Investigational Site
    São Paulo, 04266-010, Brazil
  • GSK Investigational Site
    São Paulo, 05403-000, Brazil
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8V 3M9, Canada
  • GSK Investigational Site
    Bay Roberts, Newfoundland and Labrador A0A 1G0, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3K 6R8, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L2, Canada
  • GSK Investigational Site
    Toronto, Ontario M4S 1Y2, Canada
  • GSK Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • GSK Investigational Site
    Woodstock, Ontario N4S 5P5, Canada
  • GSK Investigational Site
    Gatineau, Quebec J8Y 6S8, Canada
  • GSK Investigational Site
    Mirabel, Quebec J7J 2K8, Canada
  • GSK Investigational Site
    Pointe-Claire, Quebec H9R 4S3, Canada
  • GSK Investigational Site
    Québec City, Quebec G1E 7G9, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 2G2, Canada
  • GSK Investigational Site
    Trois-Rivieres, Quebec G8T 7A1, Canada
  • GSK Investigational Site
    Quebec, G1W 4R4, Canada
  • GSK Investigational Site
    Brno, 662 10, Czechia
  • GSK Investigational Site
    Ceske Budejovice, 370 04, Czechia
  • GSK Investigational Site
    Hradec Kralove, Czechia
  • GSK Investigational Site
    Tallinn, Estonia
  • GSK Investigational Site
    Tartu, 50106, Estonia
  • GSK Investigational Site
    Espoo, 02230, Finland
  • GSK Investigational Site
    Helsinki, 00100, Finland
  • GSK Investigational Site
    Helsinki, 00930, Finland
  • GSK Investigational Site
    Jarvenpaa, 04400, Finland
  • GSK Investigational Site
    Kokkola, 67100, Finland
  • GSK Investigational Site
    Oulu, 90220, Finland
  • GSK Investigational Site
    Pori, 28100, Finland
  • GSK Investigational Site
    Seinajoki, 60100, Finland
  • GSK Investigational Site
    Tampere, 33100, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Angers, 49000, France
  • GSK Investigational Site
    Angers, 49100, France
  • GSK Investigational Site
    Château Gontier, 53200, France
  • GSK Investigational Site
    Clermont-Ferrand, 63003, France
  • GSK Investigational Site
    Laval, 53000, France
  • GSK Investigational Site
    Montrevault, 49110, France
  • GSK Investigational Site
    Muret, 31600, France
  • GSK Investigational Site
    Murs-Erigne, 49610, France
  • GSK Investigational Site
    Nantes, 44300, France
  • GSK Investigational Site
    Rosiers d'Egletons, 19300, France
  • GSK Investigational Site
    Saint Cyr sur Loire, 37540, France
  • GSK Investigational Site
    Segré, 49500, France
  • GSK Investigational Site
    Tours, 37100, France
  • GSK Investigational Site
    Deggingen, Baden-Wuerttemberg 73326, Germany
  • GSK Investigational Site
    Gueglingen, Baden-Wuerttemberg 74363, Germany
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68161, Germany
  • GSK Investigational Site
    Tuebingen, Baden-Wuerttemberg 72074, Germany
  • GSK Investigational Site
    Wangen, Baden-Wuerttemberg 88239, Germany
  • GSK Investigational Site
    Weinheim, Baden-Wuerttemberg 69469, Germany

Showing the first 100 of 195 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ocran-Appiah J, Boutry C, Herve C, Soni J, Schuind A; ZOSTER-056 Study Group. Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients. Vaccine. 2021 Jan 3;39(1):6-10. doi: 10.1016/j.vaccine.2020.10.029. Epub 2020 Dec 1. PubMed 33277059 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Mar 2019, 35 months.

Results were first posted in Mar 2020, 11 months after primary completion.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 35 months is above that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2016
First posted
Feb 24, 2016
StartActual
Mar 16, 2016
Primary completionActual
Mar 15, 2019
CompletionActual
Mar 15, 2019
Results first posted
Mar 12, 2020
Last update
Mar 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02690207
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 24, 2016
Start date
Mar 16, 2016
Primary completion
Mar 15, 2019
Completion
Mar 15, 2019
Results posted
Mar 12, 2020
Last update
Mar 4, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion